Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02853968 · ClinicalTrials.gov registry record
Unlock the Cell: Castleman's Disease Flow Cytometry Study
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 130
- Enrollment target
NCT02853968: Completed study, sponsored by University of Pennsylvania.
NCT02853968 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02853968 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 130 participants
- Enrollment target
Study Summary
Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction. In this study, we will investigate inflammatory markers, cells, and signaling pathways in prospectively collected blood samples and/or buccal swabs or saliva using biochemical and RT-PCR techniques, proteomics, genomics, immunohistochemistry, storage for future use, cell culture treated with external stimuli, flow cytometry, and other molecular tests
Interventions
- PROCEDURE Blood draw/buccal swab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-03-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02853968
The ClinicalTrials.gov registry entry for NCT02853968 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw/buccal swab is the first listed.
NCT02853968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02853968 about?
NCT02853968 is a clinical study titled "Unlock the Cell: Castleman's Disease Flow Cytometry Study". Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction. In this study, we will investigate inflammatory markers, cells, and signaling pathways in prospectively collected blood samples and/or buccal swabs or s...
What is the current status of trial NCT02853968?
This trial is currently completed. The enrollment target is 130 participants. The study started on 2016-02. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT02853968?
The interventions under investigation include: Blood draw/buccal swab (PROCEDURE).
Who is sponsoring clinical trial NCT02853968?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.